Translational Core

翻译核心

• 批准号: 10112942
• 负责人: Markos Leggas
• 金额: $ 25.7万
• 依托单位: UNIVERSITY OF KENTUCKY
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-03-01 至 2025-01-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10112942
• 关键词: Address; Adhesions; Animals; Basic Science; Biological Assay; Biology; Biomedical Research; Centers of Research Excellence; Chemicals; Clinical; Clinical Research; Collection; Complement; Consultations; Data Analyses; Development; Devices; Disease; Doctor of Philosophy; Drug Kinetics; Excretory function; Faculty; Gap Junctions; Goals; Health; In Vitro; Infrastructure; Kentucky; Lead; Leadership; Libraries; Mentors; Mentorship; Metabolism; Methods; Microbial Biofilms; Modeling; Molecular Medicine; Natural Products; Organic Synthesis; Pharmacologic Substance; Pilot Projects; Reporter; Research; Research Design; Research Personnel; Research Support; Resources; Science; Scientist; Services; Toxic effect; Translational Research; Type IV Secretion System Pathway; Universities; Validation; absorption; antimicrobial; base; career development; clinical application; cytotoxicity; design; experimental study; faculty research; immunoregulation; innovation; instrumentation; multidisciplinary; pre-clinical; prevent; primary outcome; screening; screening services; stem; synergism; tool; transcription factor

PROJECT SUMMARY/ABSTRACT – TRANSLATIONAL CORE We propose to establish a Center of Biomedical Research Excellence (COBRE) in Pharmaceutical Research and Innovation at the University of Kentucky (UK). CPRI will serve as a comprehensive multidisciplinary center focused on translational chemical biology [the nexus of chemical biology (the application of chemical biology principles to develop validated probe/models to advance our understanding of biology) and pharmaceutical science (the application of pharmaceutical principles to advance leads/materials/devices that address unmet clinical needs)]. The COBRE will leverage and develop unique translational chemical biology research support infrastructure/expertise to facilitate junior faculty mentorship and career development, innovative biomedical research probe/tool/model/materials development and validation, and the early advancement of potential ‘translatable’ assets. Within this context, the CPRI Translational Core will provide key infrastructure and expertise to support experimental studies central to probe/lead/materials discovery. Under the co-direction of Drs. Markos Leggas and Jon Thorson, the Core will support assay design, development, validation and implementation; pilot screening campaigns; a suite of in vitro absorption, distribution, metabolism, excretion and toxicity (ADMET) assays; and first in animal ADMET/pharmacokinetics (PK) studies. Support in the Core will be tailored toward specific COBRE project/pilot needs and screening services will also leverage CPRI-exclusive compound collections (both natural products and synthetics). The Core’s services have been strategically designed to integrate with, and complement, the support provided by the CPRI Computational Core and the CPRI-affiliated COBRE for Molecular Medicine Organic Synthesis Core. Together, CPRI’s corresponding fully integrated research support capabilities and expertise will accelerate innovative, ‘translatable’ transdisciplinary research and facilitate junior investigator career development.

项目概要/摘要-翻译核心 我们建议建立一个生物医学研究卓越中心（COBRE）在药物研究 在肯塔基州大学（英国）的创新。CPRI将作为一个综合性的多学科中心 专注于转化化学生物学[化学生物学的联系（化学生物学的应用 开发经验证的探针/模型的原则，以促进我们对生物学和药物的理解 科学（应用药学原理来推进电极导线/材料/器械， 临床需要）。COBRE将利用和开发独特的转化化学生物学研究支持 基础设施/专业知识，以促进初级教师辅导和职业发展，创新的生物医学 研究探针/工具/模型/材料的开发和验证，以及潜在的早期进展 “可翻译”资产在此背景下，CPRI翻译核心将提供关键的基础设施和专业知识 支持对探测器/铅/材料发现至关重要的实验研究。在马科斯博士的指导下 Leggas和Jon Thorson，核心将支持检测设计、开发、验证和实施;试点 筛选活动;一套体外吸收、分布、代谢、排泄和毒性（ADMET） 首先在动物ADMET/药代动力学（PK）研究中进行。核心中的支持将针对 具体的COBRE项目/试点需求和筛选服务也将利用CPRI专用化合物 收藏品（包括天然产品和合成产品）。核心的服务在战略上旨在 与CPRI计算核心和CPRI附属的 COBRE分子医学有机合成核心。总之，CPRI的相应的完全集成 研究支持能力和专业知识将加速创新，'可翻译'的跨学科研究 并促进初级调查员的职业发展。